TriangleCD22CART cell (NCT04815356)
CD22CART cell trial for Hairy Cell Leukemia (NCT04815356). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
Lo que dice el vídeo
Lee la transcripción
Hairy cell leukemia is rare and usually gentle; most people respond to a week of chemotherapy and stay well for years. But a variant form shrugs it off, and once targeted drugs fail, survival is a couple of years.
The idea: turn CAR T cells, proven in other B-cell leukemias, on this one.
Hairy cells are brightly coated in a protein called CD22. The National Cancer Institute team that built the first anti-CD22 drug for this disease now fits a patient's own T cells with a receptor for it. After chemotherapy makes room, one infusion goes in.
Robert Kreitman leads it at the NIH Clinical Center in Bethesda, for adults out of standard options, asking what dose is safe. Public record; not medical advice.
¿Ya estás en un ensayo?
Se convierte en un proyecto que hay que manejar: citas, estudios de imagen, análisis, efectos secundarios y papeleo. Triangle lo mantiene organizado en un solo lugar, para ti o para quien te ayuda.
Organizar mi ensayoPrueba gratuita de 7 días, después $9 al mes. Cancela cuando quieras.
Cómo funcionan estos ensayos: qué es de verdad la fase 1 · preguntas frecuentes No es evidencia clínica.